Loading clinical trials...
Loading clinical trials...
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Conditions
Interventions
Fluticasone / Salmeterol
Placebo
+1 more
Locations
100
United States
Roxane Laboratories Research Site #30
Glendale, Arizona, United States
Roxane Laboratories Research Site #46
Phoenix, Arizona, United States
Roxane Laboratories Research Site #1
Surprise, Arizona, United States
Roxane Laboratories Research Site #13
Tempe, Arizona, United States
Roxane Laboratories Research Site #84
Bakersfield, California, United States
Roxane Laboratories Research Site #72
Costa Mesa, California, United States
Start Date
August 1, 2014
Primary Completion Date
November 1, 2015
Completion Date
November 1, 2015
Last Updated
January 23, 2018
NCT06979323
NCT06664619
NCT07431021
NCT07383896
NCT07356310
NCT06003569
Lead Sponsor
Roxane Laboratories
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions